PROS1 and COVID-19: In a phase-2 trial involving 452 outpatients with mild or moderate COVID-19, a single intravenous infusion of the neutralizing antibody LY-CoV555, which targets the S protein and was extracted from a recovered SARS-CoV-2 patient, appeared to accelerate the natural decline in viral load [38].